Abstract
We aimed to evaluate the efficacy of VSV-G pseudotyped, defective HIV-1 based lentiviral vectors for the neonatal transfer of therapeutic genes following systemic administration in Sandhoff mouse pups. Despite transgene expression in mouse brains, these animals presented with significant exacerbation and acceleration of the disease neurological phenotype. We observed an increase and acceleration in the presence of MHC-II and CD45+ cells in their brains, along with neuroinflammation, but not in control heterozygous or wild type littermates that also received the same treatment.
Original language | English |
---|---|
Pages (from-to) | 39-47 |
Number of pages | 9 |
Journal | Journal of Neuroimmunology |
Volume | 188 |
Issue number | 1-2 |
DOIs | |
State | Published - Aug 2007 |
Bibliographical note
Funding Information:We would like to thank Dr. Richard L. Proia for providing the HexB −/− knockout Sandhoff mice as well as the goat anti-HEXB antibody used in this study. This work was supported in part by a grant from NIH/NINDS number NS048339 awarded to SK.
Keywords
- Gene therapy
- Lentiviral vectors
- Lysosomal storage disorder
- Sandhoff disease
- β-hexosaminidase
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology